The North America intravenous solutions market size accounted for USD 5.84 billion in 2025 and is predicted to increase from USD 6.26 billion in 2026 to approximately USD 11.7 billion by 2035, expanding at a CAGR of 7.2% from 2026 to 2035. Growing surgical procedures, increasing at-home infusions, expanding chronic disease burden, rising demand for ready-to-use solutions, expanding healthcare expenditures, and increasing innovations are promoting the market growth.
The North America intravenous solutions refer to the manufacturing, distribution, and use of sterile liquid solutions that are administered directly into veins for a wide range of applications across the healthcare setting of North America. They offer hydration therapy, electrolyte balance management, parenteral nutrition support, and deliver various vaccines, biologics, and dialysis-related therapies. They also help in oncology treatments, pain management, neonatal care, diabetic management, and cardiovascular disease management.
The graph represents the estimated number of U.S. cancer deaths and new cases in the year 2026. It indicates that there will be a growth in the cancer burden in the U.S., which will increase the demand for effective treatment options. This, in turn, will drive the adoption of intravenous solutions for the treatment of multiple cancer types, which will ultimately promote market growth.
By product type, the crystalloid solutions segment accounted for the highest revenue share of 41% of the North America intravenous solutions market in 2025, due to their wide use for fluid replacement and maintenance of electrolyte balance. Their affordability and low risk of adverse effects also increased their acceptance rates. They were mostly used during surgeries and emergency conditions.
By nutrient composition type, the carbohydrates segment held a major revenue share of 33% of the North America intravenous solutions market in 2025, as they are considered the primary source for quick energy. They were frequently used in weakness and dehydration management. Their wide use in parenteral nutrition formulations also contributed to their demand.
By packaging type, the flexible IV bags segment contributed the biggest revenue share of 54% of the North America intravenous solutions market in 2025, driven by their lightweight and longer shelf life. Their easy disposal and reduced risk of breakages also encouraged their adoption. They were also preferred for large volume IV administrations.
By application type, the fluid & electrolyte balance segment held the largest revenue share of 30% of the North America intravenous solutions market in 2025, as the intravenous solutions were widely used in critical care treatments. They helped in regulating electrolyte levels, which increased their use during surgeries. Growth in dehydration and infection cases also increased their use.
By end user, the hospitals segment led the North America intravenous solutions market with 61% share in 2025, driven by growth in the patient volume and number of surgeries. The rise in the demand for hydration therapy, chemotherapy, and nutrition support has also increased the use of IV solutions. Advanced infrastructure, skilled personnel, and specialized departments also attracted the patients.
The North America intravenous solutions market held a considerable share in 2025 and is expected to expand rapidly during the forecast period, due to the presence of advanced healthcare infrastructure and advanced industries. Growth in cancer cases, kidney diseases, and surgical volumes also increased the demand for IV solutions. Expansion in health awareness, home healthcare, and healthcare expenditure also increased their adoption rates, enhancing the market growth.
Baxter International Inc. dominated the market with its Viaflex, Mini-bag plus, Viaflo, and Olimel products, where B. Braun Medical Inc. was its closest contender, which provided EXCEL and E3 products. ICU Medical, Inc. also maintained its position by offering LifeCare, VisIV, Liposyn, and Fleboflex, where Fresenius Kabi AG also contributed to the market growth with its Freeflex, Kabiven, and Perikabiven products.
By Product Type
By Nutrient Composition
By Packaging Type
By Application
By End User
By Osmolarity
By Route of Administration
By Patient Group
By Distribution Channel
By Region
